RecruitingObesityHealthy Lifestyle
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
Sponsor: Cedars-Sinai Medical Center
You may qualify if…
- ✓ 1. Both Sexes
- ✓ 2. Age: younger lean group 18-30 years with BMI 18.5-24.9 kg/m2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9
- ✓ 3. All races and ethnic groups
- ✓ 4. Community dwelling
- ✓ 5. Sedentary (≤1.5 h of exercise per week)
- ✓ 6. Nondiabetic (fasting plasma glucose \< 126 mg/dl, 2-h glucose during oral glucose tolerance test (OGTT) \< 140mg/dl, and A1c \< 6.5%
- ✓ 7. For all female participants who are women of childbearing potential (WOCBP), who are not pregnant or breast feeding, at least one of the following conditions must apply:
- ✓ A documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy Use of a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency (implantable progesterone-only hormone contraception, intrauterine hormone releasing system, bilateral tubal occlusion, vasectomized partner) during the intervention period of the study and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug.
You may not qualify if…
- ✕ 1. Diabetes, clinically diagnosed or HbA1c \> 6.5% and/or fasting plasma glucose \> 126 mg/dl and/or use of anti-diabetic medications.
- ✕ 2. Participating in \> 1.5 h of structured exercise/week
- ✕ 3. Unstable weight (\>3% change in last 3 months)
- ✕ 4. Neurological, musculoskeletal, or other conditions that may limit subject's ability to complete study physical assessment and training
- ✕ 5. Active autoimmune/inflammatory disease including: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, inflammatory bowel disease
- ✕ 6. Laboratory parameters outside the normal range:
- ✕ impaired kidney function (eGFR \< 30ml/min/1.73m² as calculated by the CKD-EPI equation);
- ✕ impaired liver function (AST or ALT level \> 2 times upper limit of normal (ULN);
Where it's recruiting
California
Los Angeles
Source: ClinicalTrials.gov · NCT05653258 · last updated 2026-03-18